

Strategic priorities for the OECI

Quality improvement in Cancer Care and Research

The Accreditation and Designation Programme, specifically designed for cancer centres, aims to constantly improve our cancer centres' outcomes for patients and their experience of care. Multidisciplinary working, efficient logistics and complex infrastructure to support patient pathways are needed in order to deliver high quality, patient-centred care to cancer patients. About half of the OECI Members are already included in the A&D Programme, and the present pipeline of applications indicates a steep growth in the programme, extending beyond Europe. Within Europe it comprises more than 50 of the largest centres which have treated more than 1 million patients since their accreditation, and produce more than 12,000 peer reviewed papers annually. The A&D Programme is specifically designed for cancer centres right across Europe, and is unique in certifying both care and research (and having standards certified by the International Society for Quality in Healthcare). The certified centres form an OECI Quality Network. Future impact will include publications of the Programme's experience from twelve years of quality assurance and improvement work, benchmarking, implementation research on networks, and establishing core standards for cancer care across the EU.

Outcomes Cancer Research

The Cancer Outcomes Research Working Group (COR-WG) has been activated in response to the need of collecting prospectively humanistic, clinical and economics outcomes in relevant cohorts of cancer patients, with the final aim to improve cancer outcomes in Europe.

The COR-WG will promote the foundation of a community of researchers, clinicians and other stakeholders to be translated into a flexible, efficient and up-to-date international collaboration centered on (but not limited to) routine medical and health care records, supported by a digital research infrastructure fully compliant with GDPR and local privacy laws.

The expected output is the creation of conditions to favorite the participation of OECI Members to a broad range of high quality research projects that will produce real world evidence to plan better health care interventions.

The Health Economics and Benchmarking activity relates to several policy priorities

The participation to the European Fair Pricing Network and its objectives is aligned with inputs coming from the OECI members. A further priority focuses on comparative data from member countries on real world value of cancer treatments. This activity will be supported by a common "taxonomy" of costs and outcome concepts to be elaborated during a preparation phase under discussion with OECI Members. The policies per country on (cost-)effectiveness, pricing, coverage and indications for targeted combination therapies are also included in the programme of activities carried out by the WG.

The WG membership will be involved in a project on "identifying alternative policies for price setting at market". This launch has been already discussed following a presentation where various scenarios were simulated.

The Working Group is also actively discussing the possible participation to a coveted call under the European Cancer Mission in the preparation phase as part of the incoming Horizon Europe Research Framework Programme. Generating better evidence on value, establishing registries for real word data and monitoring equitable access are the three main topics that could be part of a specific application. These goals may be achieved through a specific interaction with the OECI A&D Programme and the WG on Outcomes Cancer Research.











Patient Involvement and Partnerships

Quality improvement in cancer care and research is a major goal shared by healthcare professionals, researchers and patients. For OECI centres, patients are bringing a different and valuable perspective to the quality improvement process in hospitals, by expressing their special needs and priorities. Today, innovative cancer centres are taking initiatives, involving patients and launching collaborations with local and national patient organisations. The OECI Working Group "Collaboration for Good Practices with Patients" (CGPP) has been set up to solve recurrent challenges shared by cancer centres related to cancer care and research through dedicated, new patient-focused initiatives. The mission is to collect, analyse & disseminate successful, patient-oriented collaborative practices in cancer care and research; a "fact-tank" providing a supportive task force for OECI cancer centres that need methodological tools and expertise to implement new initiatives.

Biobanks and Molecular Pathobiology

The OECI Biobanks and Molecular Pathobiology Working Group, together with some of the major European Cancer Societies/Organisations, contributes to the continuous evolution of molecular oncology to guarantee the reproducibility of analytical methods. The WG develops specific recommendations for standardisation and validation of biomarkers and molecular analysis other than solid and liquid tissues biobanking for a better reproducible use. In order to accelerate the production of new effective protocols of treatment, a study aiming to a practical adoption of N-1 trials is underway. The WG is engaged in some European projects such as Instand-NGS for the clinical standardization of NG sequencing, SPIDIA 4P project for pre-analytical conditions of biological material, and HERCULES project on tumour heterogeneity. The WG collaborates with the OECI Accreditation and Designation Programme for a continuous update of the standards to be adopted. The OECI Pathology Day is the main annual event organised by the WG.

The OECI Board





 President Thierry Philip Paris, France	 Vice-President and Executive Secretary Giovanni Apolone Milan, Italy
 Treasurer Manuel Llombart Fuertes Valencia, Spain	 Elected Member Christian Brandts Frankfurt, Germany
 Elected Member Maja Čemazar Slovenia	 Elected Member Simon Oberst Cambridge, United Kingdom
 Elected Member Iwona Lugowska Poland	 Elected Member József Lövey Budapest, Hungary
 Elected Member Gunnar Sæter Oslo, Norway	 Elected Member Jacqueline Stouthard The Netherlands

 OECI Director Claudio Lombardo Brussels, Belgium - Genoa, Italy	 OECI Central Office Guy Storme Brussels, Belgium
---	--

Accreditation and Designation Programme



Working Groups

 Biobanks and Molecular Pathobiology Giorgio Stanta Trieste, Italy	 Cancer Outcomes Research Milena Sant Milan, Italy
 Cancer Economics and Benchmarking Wim H. van Harten Amsterdam, The Netherlands	 Collaboration for Good Practices with Patients Dominique de Valeriola Brussels, Belgium

OECI-EEIG Central Office - c/o Fondation Universitaire - 11, Rue d'Egmont
Phone: +32 2 512 0146, B-1000 Brussels, Belgium
www.oeci.eu oeci@oeci.eu

2021/7



OECI Objectives

The OECI aim is to accelerate the application of multidisciplinary personalised care approaches, to reduce morbidity and to guarantee an equitable access to care to all cancer patients, avoiding the collapse of the National Health Systems all over Europe, and supporting parallel initiatives outside the EU and in other continents.

This goal is being achieved by promoting and enhancing the concept of "comprehensiveness" and "multi-disciplinarity", supporting quality in cancer care and dynamically working in cross-cutting expertise by involving our Working Groups, our Members and promoting synergies with other cancer Organisations.

The OECI is currently geared towards creating a "network of cancer networks" where primary prevention, screening & early diagnosis, basic, translational & clinical research, collaboration for good practices with patients, biobanks and molecular pathobiology, cancer economics and centralising real-life cancer patient data are included.

The above goal is part of the Presidential proposal of an OECI evolution that may better answer to the need to work on a European Cancer Mission within the incoming Framework Programme "Horizon Europe".

Thierry Philip
OECI President




“The OECI is a non-governmental, non-profit Organisation founded in Vienna in 1979 and remodeled in 2005 into OECI-EEIG, a European Economic Interest Grouping. Today, the OECI regroups 108 Members, which include some of the most prominent European Comprehensive Cancer Centres. Several major cancer centres from the Chile, Colombia, Jordan, Russian Federation, Tanzania, Turkey, Ukraine and Viet Nam are also members of our Organisation in order to benefit from our Accreditation and Designation Programme and to be involved in the activities promoted by the Working Groups.”

The way to quality

OECI NETWORK 2021

Austria

- Comprehensive Cancer Center Vienna, Vienna

Belgium

- ★ Institut Jules Bordet (IJB), Brussels
- ★ AZ Groeninge, Kortrijk
- Oncologisch Centrum UZBrussel, Brussels
- Institut Roi Albert II Cliniques universitaires Saint-Luc, Brussels

Chile

- Instituto Oncológico Fundación Arturo López Pérez (FALP), Santiago

Colombia

- Instituto Nacional de Cancerología – ESE, Bogotá

Croatia

- Klinika za tumore Klinicki bolnički centar Sestre milosrdnice, Zagreb

Czech Republic

- ★ Masarykův onkologický ústav, Brno
- Fakultní nemocnice v Motole, Prague
- Institut biostatistiky a analýz Lékařská fakulta Masarykovy univerzity, Brno

Denmark

- ★ Vejle Sygehus, Patienternes Kræftsygehus en del af Sygehus Lillebælt, Vejle
- Kræftens Bekæmpelse Center for Kræftforskning, Copenhagen

Estonia

- ★ Sihtasutus Tartu Ülikooli Kliinikum, Tartu
- North Estonia Medical Centre, Tallin
- AS Ida-Tallinna Keskhaigla, Tallin

Finland

- ★ HUS Syöpäkeskus Helsingin Yliopistollinen Sairaala, Helsinki
- ★ TYKS Syöpäkeskus Turun Yliopistollinen Sairaala, Turku

- ★ TAYS Cancer Centre Tampere University Hospital, Tampere
- ★ KYS Syövänhoitokeskus Kuopion Yliopistollinen Sairaala, Kuopio
- ★ OYS Oulun Yliopistollinen Sairaala, Oulu

France

- ★ Centre Léon Bérard, Lyon
- ★ Institut Curie, Paris
- ★ Institut Paoli – Calmettes, Marseille
- ★ Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse
- ★ Centre François Baclesse, Caen
- ★ APHP-CARPÉM Institute, Paris
- ★ Institut de Cancérologie de l'Ouest (ICO), Angers - Saint Herblain
- ★ Association Toulousaine de Oncologie Publique (ATOP), Toulouse
- ★ Assistance Publique - Hôpitaux de Paris Institut Universitaire de Cancérologie APHP. Sorbonne Université, Paris
- ★ Centre de lutte contre le cancer Eugène Marquis, Rennes
- Gustave Roussy, Villejuif
- Institut de cancérologie Strasbourg Europe ICANS, Strasbourg
- Centre Jean Perrin, Clermont-Ferrand
- Institut du Cancer de Montpellier (ICM), Montpellier
- Institut Godinot, Reims
- Centre de Lutte Contre le Cancer Georges-François Leclerc, Dijon
- Centre Henri Becquerel, Rouen
- Institut Sainte Catherine, Avignon

- Centre de lutte contre le cancer Eugène Marquis, Rennes
- Gustave Roussy, Villejuif
- Institut de cancérologie Strasbourg Europe ICANS, Strasbourg
- Centre Jean Perrin, Clermont-Ferrand
- Institut du Cancer de Montpellier (ICM), Montpellier
- Institut Godinot, Reims
- Centre de Lutte Contre le Cancer Georges-François Leclerc, Dijon
- Centre Henri Becquerel, Rouen
- Institut Sainte Catherine, Avignon

Germany

- Deutsches Krebsforschungszentrum (DKFZ), Heidelberg
- Nationales Centrum für Tumorerkrankungen Dresden NCT/UCC, Dresden

- Charité Comprehensive Cancer Center, Berlin
- Universitäres Centrum für Tumorerkrankungen (UCT), Frankfurt

Hungary

- ★ Országos Onkológiai Intézet, Budapest
- Országos Korányi TBC és Pulmonológiai Intézet, Budapest

Ireland

- ★ Trinity St. James's Cancer Institute, Dublin
- ★ Beaumont Hospital, Dublin
- Saolta University Cancer Network, Galway University Hospitals, Galway

Italy

- ★ Centro di Riferimento Oncologico, Istituto Nazionale Tumori, Aviano
- ★ IRCCS Ospedale Policlinico San Martino, Genova
- ★ Istituto Europeo di Oncologia, Milano
- ★ Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- ★ Istituto Nazionale Tumori Regina Elena, Roma
- ★ Istituto Oncologico Veneto IRCCS-IOV, Padova
- ★ IRCCS Istituto Clinico Humanitas, Rozzano (Milano)
- ★ Azienda Unità Sanitaria Locale di Reggio Emilia - IRCCS Istituto in Tecnologie Avanzate e Modelli Assistenziali in Oncologia, Reggio Emilia
- ★ Istituto Nazionale Tumori IRCCS "Fondazione G.Pascale" (INT-Pascale), Napoli
- ★ Istituto Tumori Giovanni Paolo II, Istituto di Ricovero e Cura a Carattere Scientifico, Bari
- ★ IRCCS, Centro di Riferimento Oncologico della Basilicata (CROB), Rionero in Vulture (Potenza)
- ★ Istituto di Candiolo FPO-IRCCS, Candiolo (Torino)

- ★ Istituto Nazionale Tumori IRCCS "Fondazione G.Pascale" (INT-Pascale), Napoli
- ★ Istituto Tumori Giovanni Paolo II, Istituto di Ricovero e Cura a Carattere Scientifico, Bari
- ★ IRCCS, Centro di Riferimento Oncologico della Basilicata (CROB), Rionero in Vulture (Potenza)
- ★ Istituto di Candiolo FPO-IRCCS, Candiolo (Torino)

- ★ Istituto Nazionale Tumori IRCCS "Fondazione G.Pascale" (INT-Pascale), Napoli
- ★ Istituto Tumori Giovanni Paolo II, Istituto di Ricovero e Cura a Carattere Scientifico, Bari
- ★ IRCCS, Centro di Riferimento Oncologico della Basilicata (CROB), Rionero in Vulture (Potenza)
- ★ Istituto di Candiolo FPO-IRCCS, Candiolo (Torino)

- ★ Istituto Nazionale Tumori IRCCS "Fondazione G.Pascale" (INT-Pascale), Napoli
- ★ Istituto Tumori Giovanni Paolo II, Istituto di Ricovero e Cura a Carattere Scientifico, Bari
- ★ IRCCS, Centro di Riferimento Oncologico della Basilicata (CROB), Rionero in Vulture (Potenza)
- ★ Istituto di Candiolo FPO-IRCCS, Candiolo (Torino)

- ★ Istituto Nazionale Tumori IRCCS "Fondazione G.Pascale" (INT-Pascale), Napoli
- ★ Istituto Tumori Giovanni Paolo II, Istituto di Ricovero e Cura a Carattere Scientifico, Bari
- ★ IRCCS, Centro di Riferimento Oncologico della Basilicata (CROB), Rionero in Vulture (Potenza)
- ★ Istituto di Candiolo FPO-IRCCS, Candiolo (Torino)

- ★ IRCCS Ospedale Sacro Cuore Don Calabria, Negrar di Valpolicella (Verona)
- Ospedale San Raffaele (OSR), Milano
- Fondazione IFOM - FIRC Institute of Molecular Oncology, Milano
- IRCCS Istituto Romagnolo per lo Studio dei Tumori «Dino Amadori» - IRST s.r.l., Meldola (Forlì-Cesena)
- Istituto Oncologico del Mediterraneo s.p.a. (IOM), Viagrande (Catania)
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma
- IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Milano
- Istituto Dermatologico San Gallicano, Roma
- Fondazione I.R.C.C.S. Policlinico San Matteo, Pavia

- Ospedale San Raffaele (OSR), Milano
- Fondazione IFOM - FIRC Institute of Molecular Oncology, Milano
- IRCCS Istituto Romagnolo per lo Studio dei Tumori «Dino Amadori» - IRST s.r.l., Meldola (Forlì-Cesena)
- Istituto Oncologico del Mediterraneo s.p.a. (IOM), Viagrande (Catania)
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma
- IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Milano
- Istituto Dermatologico San Gallicano, Roma
- Fondazione I.R.C.C.S. Policlinico San Matteo, Pavia

- Ospedale San Raffaele (OSR), Milano
- Fondazione IFOM - FIRC Institute of Molecular Oncology, Milano
- IRCCS Istituto Romagnolo per lo Studio dei Tumori «Dino Amadori» - IRST s.r.l., Meldola (Forlì-Cesena)
- Istituto Oncologico del Mediterraneo s.p.a. (IOM), Viagrande (Catania)
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma
- IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Milano
- Istituto Dermatologico San Gallicano, Roma
- Fondazione I.R.C.C.S. Policlinico San Matteo, Pavia

- Ospedale San Raffaele (OSR), Milano
- Fondazione IFOM - FIRC Institute of Molecular Oncology, Milano
- IRCCS Istituto Romagnolo per lo Studio dei Tumori «Dino Amadori» - IRST s.r.l., Meldola (Forlì-Cesena)
- Istituto Oncologico del Mediterraneo s.p.a. (IOM), Viagrande (Catania)
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma
- IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Milano
- Istituto Dermatologico San Gallicano, Roma
- Fondazione I.R.C.C.S. Policlinico San Matteo, Pavia

- Ospedale San Raffaele (OSR), Milano
- Fondazione IFOM - FIRC Institute of Molecular Oncology, Milano
- IRCCS Istituto Romagnolo per lo Studio dei Tumori «Dino Amadori» - IRST s.r.l., Meldola (Forlì-Cesena)
- Istituto Oncologico del Mediterraneo s.p.a. (IOM), Viagrande (Catania)
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma
- IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Milano
- Istituto Dermatologico San Gallicano, Roma
- Fondazione I.R.C.C.S. Policlinico San Matteo, Pavia

- Ospedale San Raffaele (OSR), Milano
- Fondazione IFOM - FIRC Institute of Molecular Oncology, Milano
- IRCCS Istituto Romagnolo per lo Studio dei Tumori «Dino Amadori» - IRST s.r.l., Meldola (Forlì-Cesena)
- Istituto Oncologico del Mediterraneo s.p.a. (IOM), Viagrande (Catania)
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma
- IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Milano
- Istituto Dermatologico San Gallicano, Roma
- Fondazione I.R.C.C.S. Policlinico San Matteo, Pavia

- Ospedale San Raffaele (OSR), Milano
- Fondazione IFOM - FIRC Institute of Molecular Oncology, Milano
- IRCCS Istituto Romagnolo per lo Studio dei Tumori «Dino Amadori» - IRST s.r.l., Meldola (Forlì-Cesena)
- Istituto Oncologico del Mediterraneo s.p.a. (IOM), Viagrande (Catania)
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma
- IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Milano
- Istituto Dermatologico San Gallicano, Roma
- Fondazione I.R.C.C.S. Policlinico San Matteo, Pavia

- Ospedale San Raffaele (OSR), Milano
- Fondazione IFOM - FIRC Institute of Molecular Oncology, Milano
- IRCCS Istituto Romagnolo per lo Studio dei Tumori «Dino Amadori» - IRST s.r.l., Meldola (Forlì-Cesena)
- Istituto Oncologico del Mediterraneo s.p.a. (IOM), Viagrande (Catania)
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma
- IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Milano
- Istituto Dermatologico San Gallicano, Roma
- Fondazione I.R.C.C.S. Policlinico San Matteo, Pavia

- Ospedale San Raffaele (OSR), Milano
- Fondazione IFOM - FIRC Institute of Molecular Oncology, Milano
- IRCCS Istituto Romagnolo per lo Studio dei Tumori «Dino Amadori» - IRST s.r.l., Meldola (Forlì-Cesena)
- Istituto Oncologico del Mediterraneo s.p.a. (IOM), Viagrande (Catania)
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma
- IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Milano
- Istituto Dermatologico San Gallicano, Roma
- Fondazione I.R.C.C.S. Policlinico San Matteo, Pavia

- Ospedale San Raffaele (OSR), Milano
- Fondazione IFOM - FIRC Institute of Molecular Oncology, Milano
- IRCCS Istituto Romagnolo per lo Studio dei Tumori «Dino Amadori» - IRST s.r.l., Meldola (Forlì-Cesena)
- Istituto Oncologico del Mediterraneo s.p.a. (IOM), Viagrande (Catania)
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma
- IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Milano
- Istituto Dermatologico San Gallicano, Roma
- Fondazione I.R.C.C.S. Policlinico San Matteo, Pavia

- Ospedale San Raffaele (OSR), Milano
- Fondazione IFOM - FIRC Institute of Molecular Oncology, Milano
- IRCCS Istituto Romagnolo per lo Studio dei Tumori «Dino Amadori» - IRST s.r.l., Meldola (Forlì-Cesena)
- Istituto Oncologico del Mediterraneo s.p.a. (IOM), Viagrande (Catania)
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma
- IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Milano
- Istituto Dermatologico San Gallicano, Roma
- Fondazione I.R.C.C.S. Policlinico San Matteo, Pavia

- Ospedale San Raffaele (OSR), Milano
- Fondazione IFOM - FIRC Institute of Molecular Oncology, Milano
- IRCCS Istituto Romagnolo per lo Studio dei Tumori «Dino Amadori» - IRST s.r.l., Meldola (Forlì-Cesena)
- Istituto Oncologico del Mediterraneo s.p.a. (IOM), Viagrande (Catania)
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma
- IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Milano
- Istituto Dermatologico San Gallicano, Roma
- Fondazione I.R.C.C.S. Policlinico San Matteo, Pavia

- Ospedale San Raffaele (OSR), Milano
- Fondazione IFOM - FIRC Institute of Molecular Oncology, Milano
- IRCCS Istituto Romagnolo per lo Studio dei Tumori «Dino Amadori» - IRST s.r.l., Meldola (Forlì-Cesena)
- Istituto Oncologico del Mediterraneo s.p.a. (IOM), Viagrande (Catania)
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma
- IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Milano
- Istituto Dermatologico San Gallicano, Roma
- Fondazione I.R.C.C.S. Policlinico San Matteo, Pavia

- Ospedale San Raffaele (OSR), Milano
- Fondazione IFOM - FIRC Institute of Molecular Oncology, Milano
- IRCCS Istituto Romagnolo per lo Studio dei Tumori «Dino Amadori» - IRST s.r.l., Meldola (Forlì-Cesena)
- Istituto Oncologico del Mediterraneo s.p.a. (IOM), Viagrande (Catania)
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma
- IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Milano
- Istituto Dermatologico San Gallicano, Roma
- Fondazione I.R.C.C.S. Policlinico San Matteo, Pavia

- Ospedale San Raffaele (OSR), Milano
- Fondazione IFOM - FIRC Institute of Molecular Oncology, Milano
- IRCCS Istituto Romagnolo per lo Studio dei Tumori «Dino Amadori» - IRST s.r.l., Meldola (Forlì-Cesena)
- Istituto Oncologico del Mediterraneo s.p.a. (IOM), Viagrande (Catania)
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma
- IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Milano
- Istituto Dermatologico San Gallicano, Roma
- Fondazione I.R.C.C.S. Policlinico San Matteo, Pavia

- Ospedale San Raffaele (OSR), Milano
- Fondazione IFOM - FIRC Institute of Molecular Oncology, Milano
- IRCCS Istituto Romagnolo per lo Studio dei Tumori «Dino Amadori» - IRST s.r.l., Meldola (Forlì-Cesena)
- Istituto Oncologico del Mediterraneo s.p.a. (IOM), Viagrande (Catania)
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma
- IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Milano
- Istituto Dermatologico San Gallicano, Roma
- Fondazione I.R.C.C.S. Policlinico San Matteo, Pavia

Romania

- ★ The "Prof. Dr. Ion Chiricuta" Institute of Oncology (IOCN), Cluj-Napoca
- SC RTC Radiology Therapeutic Center Amethyst Radiotherapy, Otopeni

Russia Federation

- Tatarstan Cancer Center "TCC", Kazan
- N.N. Blokhin Russian Cancer Research Centre, Moscow
- National Medical Research Radiological Centre (NMRRC), Moscow

Serbia

- Oncology Institute of Vojvodina, Sremska Kamenica

Slovakia

- Biomedicinske centrum Slovenskej akadémie vied, Bratislava

Slovenia

- ★ Onkološki Inštitut Ljubljana, Ljubljana

Spain

- ★ Fundación Instituto Valenciano de Oncología IVO, Valencia
- ★ Vall d'Hebron Barcelona Campus Hospitalari, Barcelona
- Institut Català d'Oncologia ICO, L'Hospitalet de Llobregat (Barcelona)

Sweden

- ★ Karolinska Institute and University Hospital, Stockholm
- ★ Skånes Universitetssjukhus, Lund
- ★ Sahlgrenska University Hospital, Göteborg
- Uppsala University Hospital, Uppsala
- Norrlands Universitetssjukhus, Umeå

Switzerland

- Comprehensive Cancer Center Zürich (CCCZ), Zürich

Tanzania

- The Aga Khan Hospital, Dar es Salaam

The Netherlands

- ★ Netherlands Cancer Institute, Amsterdam
- ★ Maastricht University Medical Centre+, Maastricht
- ★ University Medical Center Groningen Comprehensive Cancer Center (UMCG-CCC), Groningen
- Erasmus MC Cancer Institute, Rotterdam
- IKNL Integraal Kankercentrum Nederland, Utrecht
- Radboudumc Centrum voor Oncologie, Nijmegen
- Rijnstate, Arnhem

Turkey

- ★ Anadolu Saglik Merkezi, Kocaeli
- Dokuz Eylul Üniversitesi Onkoloji Enstitüsü, Izmir

Ukraine

- RE Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology of National Academy of Sciences of Ukraine (IEPOR), Kyiv

United Kingdom

- ★ The Christie NHS Foundation Trust, Manchester
- ★ Cambridge Cancer Centre, Cambridge
- ★ King's Health Partners Integrated Cancer Centre, London

Viet Nam

- Bệnh viện K Viet Nam National Cancer Hospital, Hanoi

The OECI Network

- ★ OECI Members A&D certified Comprehensive Cancer Centre
- ★ OECI Members A&D certified Cancer Centre
- ★ OECI Members in the A&D process
- Other OECI Members

